Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia.
Essentials Antiangiogenic drugs are indicated as therapies for hereditary hemorrhagic telangiectasia. We interrogated the response to four antiangiogenic drugs for anemia and intestinal bleeding. Sorafenib and a pazopanib analog significantly improved while erlotinib worsened anemia. Some oral antiangiogenic drugs were effective in reducing intestinal bleeding.



Background Epistaxis and gastrointestinal (GI) tract hemorrhages are common symptoms of aged hereditary hemorrhagic telangiectasia (HHT) patients that result in anemia. Clinical as well as animal studies have suggested that vascular endothelial growth factor (VEGF) neutralizing antibodies lessen hemorrhage associated with adult-onset arteriovenous malformations (AVMs). Objectives The goal of this study is to evaluate potential therapeutic effects of oral delivery of four antiangiogenic tyrosine-kinase inhibitors (TKIs) in the development of adult-onset AVMs in a murine model of HHT. Methods An adult activin receptor-like kinase 1 (Alk1)-inducible knockout (iKO) model was utilized to evaluate the effect of oral administration of sorafenib, sunitinib, erlotinib and a pazopanib analog (GW771806) on hemoglobin level, GI hemorrhages and formation of wound-induced skin AVMs. Results and Conclusions Sorafenib and GW771806 significantly improved, yet erlotinib worsened, anemia and GI-bleeding in the Alk1-iKO model. However, none of these TKIs appeared to be effective for inhibiting the development of wound-induced skin AVMs. Taken together, these results suggest that oral delivery of antiangiogenic TKIs is selectively more effective for GI bleeding than mucocutaneous AVMs, and it may provide an experimental basis for selective therapeutic options depending on the symptoms of HHT.
Department of Physiology and Functional Genomics, College of Medicine, University of Florida, Gainesville, FL, USA.
Y H
YH
Kim
Department of Aging, College of Medicine, University of Florida, Gainesville, FL, USA.|Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Korea.
M-J
MJ
Kim
Department of Physiology and Functional Genomics, College of Medicine, University of Florida, Gainesville, FL, USA.|Department of Medical IT Convergence Engineering, Kumoh National Institute of Technology, Gumi, Korea.
S-W
SW
Choe
GlaxoSmithKline Laboratories, Metabolic Pathways and Cardiovascular Unit, King of Prussia, PA, USA.
D
D
Sprecher
Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Korea.
Y J
YJ
Lee
Department of Physiology and Functional Genomics, College of Medicine, University of Florida, Gainesville, FL, USA.|GlaxoSmithKline Laboratories, Metabolic Pathways and Cardiovascular Unit, King of Prussia, PA, USA.
S
S
P Oh
D030201:Activin Receptors, Type I / Q000378:metabolism; D030301:Activin Receptors, Type II; D000284:Administration, Oral; D000287:Administration, Topical; D000740:Anemia / Q000188:drug therapy / Q000235:genetics; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D001165:Arteriovenous Malformations; D004195:Disease Models, Animal; D000069347:Erlotinib Hydrochloride / Q000008:administration & dosage; D006471:Gastrointestinal Hemorrhage; D006454:Hemoglobins / Q000032:analysis; D007091:Image Processing, Computer-Assisted; D007191:Indazoles / Q000008:administration & dosage; D051379:Mice; D018345:Mice, Knockout; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives; D010671:Phenylurea Compounds / Q000008:administration & dosage; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage; D012867:Skin / Q000098:blood supply; D000077157:Sorafenib; D013449:Sulfonamides / Q000008:administration & dosage; D013450:Sulfones / Q000008:administration & dosage; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000188:drug therapy* / Q000235:genetics*; D014443:Tyrosine / Q000737:chemistry; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D014945:Wound Healing
D020533:Angiogenesis Inhibitors; C580765:GW771806; D006454:Hemoglobins; D007191:Indazoles; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D013450:Sulfones; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D014443:Tyrosine; C516667:pazopanib; D000077157:Sorafenib; D000069347:Erlotinib Hydrochloride; D030201:Activin Receptors, Type I; D030301:Activin Receptors, Type II; C498931:Acvrl1 protein, mouse
activin receptors; anemia; angiogenesis inhibitors; arteriovenous malformation; hereditary hemorrhagic; telangiectasia